Avagacestat is a selective gamma-secretase inhibitor that has been investigated for its potential role in the treatment of Alzheimer’s disease. As an oxadiazole-based compound, it works by modulating amyloid-beta… Read more
Avagacestat is a selective gamma-secretase inhibitor that has been investigated for its potential role in the treatment of Alzheimer’s disease. As an oxadiazole-based compound, it works by modulating amyloid-beta production, making it a critical subject in neurodegenerative research. This category provides access to high-quality reference standards of Avagacestat, including its pharmacopeial and non-pharmacopeial impurities, as well as stable isotope-labelled compounds. These materials are essential for pharmaceutical laboratories performing rigorous impurity profiling, method validation, and quality control. By using these analytical standards, researchers can accurately identify, quantify, and monitor degradation products and metabolic pathways in complex matrices. Providing these precise, documented materials supports the development of robust analytical methods necessary for investigating therapeutic compounds in both clinical and preclinical settings.